1. Home
  2. JFR vs TNDM Comparison

JFR vs TNDM Comparison

Compare JFR & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Floating Rate Income Fund

JFR

Nuveen Floating Rate Income Fund

HOLD

Current Price

$7.65

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo Tandem Diabetes Care Inc.

TNDM

Tandem Diabetes Care Inc.

HOLD

Current Price

$17.18

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JFR
TNDM
Founded
2004
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
JFR
TNDM
Price
$7.65
$17.18
Analyst Decision
Buy
Analyst Count
0
19
Target Price
N/A
$28.00
AVG Volume (30 Days)
491.3K
1.6M
Earning Date
01-01-0001
05-07-2026
Dividend Yield
11.31%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,014,736,000.00
Revenue This Year
N/A
$8.11
Revenue Next Year
N/A
$11.85
P/E Ratio
N/A
N/A
Revenue Growth
N/A
7.93
52 Week Low
$7.16
$10.00
52 Week High
$8.55
$29.65

Technical Indicators

Market Signals
Indicator
JFR
TNDM
Relative Strength Index (RSI) 45.62 55.21
Support Level $7.58 $14.44
Resistance Level $7.72 $20.79
Average True Range (ATR) 0.04 0.97
MACD -0.01 0.21
Stochastic Oscillator 0.00 68.67

Price Performance

Historical Comparison
JFR
TNDM

About JFR Nuveen Floating Rate Income Fund

Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income. The fund invests a majority of its managed assets in secured Senior Loans and unsecured Senior Loans, with an average duration of one year or less, in which unsecured Senior Loans will be, at the time of investment, investment grade quality.

About TNDM Tandem Diabetes Care Inc.

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.

Share on Social Networks: